Galapagos, BioReliance, Parexel, MDS Pharma Services and PharmEng - People on the move
have all had people on the move in the world of pharmaceutical
outsourcing.
Early-phase services firm BioReliance has named Darryl Goss as its vice president of toxicology/laboratory animal diagnostic services (LADS), a position created to lead this newly-formed business unit. He moves from a role within BioReliance of vice president of global process excellence and will continue to serve on the company's operating committee and report to David Dodd, president, CEO and chairman. At the same time, two other staff members have moved roles. David McClelland has been appointed as director of genetic toxicology operations and will be responsible for all laboratory operations in support of gene toxicology services, while David Bruning has been appointed as senior director of business operations. Contract research organisation (CRO) Parexel has announced that Larry Ereshefsky and Malek Bajbouj have been appointed as vice presidents of Clinical Pharmacology Consulting Services in the company's international clinical pharmacology business. In their new roles the pair will advise clients on early phase clinical development in the central nervous system (CNS) therapeutic area, including psychiatry, neuropsychopharmacology, and neurophysiology clinical studies, said the firm. Ereshefsky will be based at Parexel's Clinical Pharmacology Research Unit in Los Angeles, US and Bajbouj will reside at the comparable unit in Berlin, Germany. "Clients increasingly rely on our experts to help identify and select the most promising compounds in the Phase I and Proof of Concept stages. These decisions are based on demonstrating safety and signals of efficacy as early as possible in the drug development process," said Herman Scholtz, corporate vice president and worldwide head of Clinical Pharmacology at Parexel. MDS Pharma Services has recently hired Teresa Winslow as senior vice president of global business development along with James Miskel as vice president of strategy and corporate development. Prior to her new appointment, Winslow was president of Dendrite Americas and senior vice president of Dendrite International, a pharmaceutical industry-focused sales force and marketing effectiveness solutions firm. Miskel joined MDS from Wyeth Pharmaceuticals, where he was assistant vice president for Business Planning and Strategy. Contract manufacturer PharmEng International has hired John Durham as corporate vice president of business development for its subsidiary Keata Pharma. Prior to joining Keata, John most recently held the position of president of the Draxis Pharma division of Draxis Health and was responsible for the divisions pharmaceutical contract manufacturing operations including business development, strategic planning, supply chain and logistics. Finally, Galapagos, the parent company of contract research services firm BioFocus DPI, has recruited Piet Wigerinck as senior vice president of development. As a member of Galapagos' executive team, Wigerinck will oversee the development of Galapagos' drug candidates, including preclinical development, chemistry manufacturing and control (CM&C), regulatory aspects, and clinical development, said the firm. Wigerinck joins Galapagos from Tibotec in Belgium - a subsidiary of Johnson & Johnson - where he served as vice president of Drug Discovery, Early Development and CM&C, and was also a member of the management board.
